3-溴-5-甲基-2-苯氧基吡啶 | 1018782-87-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-溴-5-甲基-2-苯氧基吡啶
• 英文名称: 3-bromo-5-methyl-2-phenoxypyridine
• 英文别名: 3-Bromo-5-methyl-2-phenoxy-pyridine
• CAS: 1018782-87-0
• 化学式: C₁₂H₁₀BrNO
• 分子量: 264.121
• InChiKey: RENBNYGDWGAGMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  314.4±42.0 °C(Predicted)
• 密度：
  1.422±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-溴-5-甲基-2-苯氧基吡啶 在 ammonium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 偶氮二异丁腈 、 sodium carbonate 作用下， 以 四氯化碳 、 乙醇 、 水 、 甲苯 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  6-Alkoxy-5-aryl-3-pyridinecarboxamides, a New Series of Bioavailable Cannabinoid Receptor Type 1 (CB1) Antagonists Including Peripherally Selective Compounds

  摘要：

  We identified 6-alkoxy-5-aryl-3-pyridinecarboxamides as potent CB1 receptor antagonists with high selectivity over CB2 receptors. The series was optimized to reduce lipophilicity compared to rimonabant to achieve peripherally active molecules with minimal central effects. Several compounds that showed high plasma exposures in rats were evaluated in vivo to probe the contribution of central vs peripheral CB1 agonism to metabolic improvement. Both rimonabant and 14g, a potent brain penetrant CB1 receptor antagonist, significantly reduced the rate of body weight gain. However, 14h, a molecule with markedly reduced brain exposure, had no significant effect on body weight. PK studies confirmed similarly high exposure of both 14h and 14g in the periphery but 10-fold lower exposure in the brain for 14h. On the basis of these data, which are consistent with reported effects in tissue-specific CB1 receptor KO mice, we conclude that the metabolic benefits of CB1 receptor antagonists are primarily centrally mediated as originally believed.

  DOI：

  10.1021/jm4010708
• 作为产物：
  描述：

  2-氯-3-溴-5-甲基吡啶 在 sodium hydride 作用下， 以 异丁酰胺 为溶剂， 反应 29.0h， 生成 3-溴-5-甲基-2-苯氧基吡啶
  参考文献：
  名称：

  3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents

  摘要：

  本发明涉及一种提高HDL胆固醇的方法，包括向需要的患者施用以下公式的化合物： 其中A、G、R1至R8和R17如描述中所定义。

  公开号：

  US20080085906A1

文献信息

• Pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
  申请人：Hoffmann-La Roche Inc.

  公开号：US08188093B2

  公开（公告）日：2012-05-29

  The present invention relates to a method of raising HDL cholesterol comprising administering to a patient in need thereof a compound of the formula wherein A, G, R1 to R8 and R17 are as defined in the description.

  本发明涉及一种提高高密度脂蛋白胆固醇的方法，包括向需要的患者给予以下化合物的治疗，其化学式如下：其中A、G、R1至R8和R17的定义见说明书。
• 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents
  申请人：Hoffmann-La Roche Inc.

  公开号：US07812028B2

  公开（公告）日：2010-10-12

  The present invention relates to a method of raising HDL cholesterol comprising administering to a patient in need thereof a compound of the formula wherein A, G, R1 to R8 and R17 are as defined in the description.

  本发明涉及一种提高高密度脂蛋白胆固醇的方法，包括向需要的患者给予以下式子中的化合物：其中A、G、R1至R8和R17的定义见说明书。
• 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents
  申请人：Andjelkovic Mirjana

  公开号：US20100267745A1

  公开（公告）日：2010-10-21

  The present invention relates to a method of raising HDL cholesterol comprising administering to a patient in need thereof a compound of the formula wherein A, G, R 1 to R 8 and R 17 are as defined in the description.

  本发明涉及一种提高HDL胆固醇的方法，包括向需要的患者给予下式化合物： 其中A、G、R1至R8和R17如描述中所定义。
• 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS
  申请人：Andjelkovic Mirjana

  公开号：US20090143409A1

  公开（公告）日：2009-06-04

  The present invention relates to a method of raising HDL cholesterol comprising administering to a patient in need thereof a compound of the formula wherein A, G, R 1 to R 8 and R 17 are as defined in the description.

  本发明涉及一种提高HDL胆固醇的方法，包括向需要的患者给予以下式子中的化合物：其中A、G、R1到R8和R17如描述中所定义。
• N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS
  申请人：Active Biotech AB

  公开号：US20160115158A1

  公开（公告）日：2016-04-28

  A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  化合物(I)的配方，或其药学上可接受的盐和包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴如RAGE、TLR4和EMMPRIN之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病中有用。